Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors

Cellular Immunology

Volumn 272, Issue 2, 2012, Pages 275-282

  Hargadon, Kristian M ^a   Forrest, Osric A ^a   Reddy, Pranay R ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

Activation; Cancer; Chemokine; Cytokine; Dendritic cell; Maturation

Indexed keywords

CHEMOKINE; CYTOKINE; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL ACTIVATION; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; LIPOPOLYSACCHARIDES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

MURINAE;

EID: 83955164193     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.10.003     Document Type: Article

References (47)

1. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
2. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
3. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
4. + T cells. Nat. Immunol. 2001, 2:1010-1017.
5. Schmidt C.S., Mescher M.F. Peptide antigen priming of naïve, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 2002, 168:5521-5529.
6. Curtsinger J.M., Valenzuela J.O., Agarwal P., Lins D., Mescher M.F. Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 2005, 174:4465-4469.
7. Joffre O., Nolte M.A., Sporri R., Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 2009, 227:234-247.
8. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D.E., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002, 195:423-435.
9. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R.M. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 1999, 96:2233-2238.
10. Radoja S., Saio M., Schaer D., Koneru M., Vukmanovic S., Frey A.B. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 2001, 167:5042-5051.
11. Blohm U., Roth E., Brommer K., Dumrese T., Rosenthal F.M., Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J. Immunol. 2002, 169:5522-5530.
12. Mortarini R., Piris A., Maurichi A., Molla A., Bersani I., Bono A., Bartoli C., Santinami M., Lombardo C., Ravagnani F., Cascinelli N., Parmiani G., Anichini A. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003, 63:2535-2545.
13. Anichini A., Scarito A., Molla A., Parmiani G., Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J. Immunol. 2003, 171:2134-2141.
14. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol. Immunother. 2004, 53:865-878.
15. Hargadon K.M., Brinkman C.C., Sheasley-O'neill S.L., Nichols L.A., Bullock T.N., Engelhard V.H. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J. Immunol. 2006, 177:6081-6090.
16. Rabinovich G., Gabrilovich D., Sotomayor E. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
17. Ferguson A., Nichols L., Zarling A., Thompson E., Brinkman C., Hargadon K., Bullock T., Engelhard V.H. Strategies and challenges in eliciting immunity to melanoma. Immunol. Rev. 2008, 222:28-42.
18. Shen Z., Reznikoff G., Dranoff G., Rock K. Cloned dendritic cells can present exogenous antigens on both MHC class I and MHC class II molecules. J. Immunol. 1997, 158:2723-2730.
19. V. MacKay, E. Moore, Immortalized Dendritic Cells. U.S. Patent 5648,219, 1997.
20. van Helden S., van Leeuwen F., Figdor C. Human and murine model cell lines for dendritic cell biology evaluated. Immunol. Lett. 2008, 117:191-197.
21. Tianpei H., Tang C., Xu S., Moyana T., Xiang J. Interferon γ stimulates maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cell. Mol. Immunol. 2007, 4:105-111.
22. Rhule A., Rase B., Smith J., Shepherd D. Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng. J. Ethnopharm. 2008, 116:179-186.
23. Jiang X., Shen C., Rey-Ladino J., Yu H., Brunham R. Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in chlamydia muridarum antigen presentation and induction of protective immunity. Infect. Immun. 2008, 76:2392-2401.
24. Alshamsan A., Hamdy S., Das S., Lavasanifar A., Samuel J., El-Kadi A. Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J. Pharm. Pharmaceut. Sci. 2010, 13:21-26.
25. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975, 35:218-224.
26. Knisely T.L., Niederkorn J.Y. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma. Invest. Ophthalmol. Vis. Sci. 1990, 31:247-257.
27. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92:4778-4791.
28. Almand B., Clark J.I., Nikitina E., Van B.J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
29. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002, 168:4333-4343.
30. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
31. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
32. Sharma S., Stolina M., Yang S.-C., Baratelli F., Lin J.F., Atianzar K., Luo J., Zhu L., Lin Y., Huang M., Dohadwala M., Batra R.K., Dubinett S.M. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 2003, 9:961-968.
33. Jackson A.M., Mulcahy L.A., Zhu X.W., O'Donnell D., Patel P.M. Tumour-mediated disruption of dendritic cell function: Inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int. J. Cancer 2008, 123:623-632.
34. Chen X., Oppenheim J.J. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr. Dir. Autoimmun. 2010, 11:119-134.
35. Dufour J.H., Dziejman M., Lie M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 2002, 168:3195-3204.
36. Angiolillo A.L., Sqadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., Kleinman H.K., Reaman G.H., Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 1995, 182:155-162.
37. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993, 260:355-358.
38. Uguccioni M., D'Apuzzo M., Loetscher M., Dewald B., Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-a alpha and MIP-1 beta on human monocytes. Eur. J. Immunol. 1995, 25:64-68.
39. Murphy P.M., Baggiolini M., Charo IF I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
40. Allavena P., Bianchi G., Zhou D., Van Damme J., Jilek P., Sozzani S., Mantovani A. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2, and -3. Eur. J. Immunol. 1994, 24:3233-3236.
41. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 1994, 91:3652-3656.
42. Kuna P., Reddigari S.R., Rucinski D., Oppenheim J.J., Kaplan A.P. Monocyte chmeotactic and activating factor is a potent histamine-releasing factor for human basophils. J. Exp. Med. 1992, 175:489-493.
43. Zhang T., Somasundaram R., Berencsi K., Caputo L., Gimotty P., Rani P., Guerry D., Swobodo R., Herlyn D. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur. J. Immunol. 2006, 36:457-467.
44. Yang L., Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 2004, 92:13-27.
45. Peter I., Mezzacasa A., LeDonne P., Dummer R., Hemmi S. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res. 2001, 11:21-30.
46. Yamaguchi Y., Tsumura H., Miwa M., Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997, 15:144-153.
47. Geissmann F., Revy P., Regnault A A., Lepelletier Y., Dy M., Brousse N., Amigorena S., Hermine O., Durandy A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 1999, 162:4567-4575.